(0.29%) 5 169.75 points
(0.24%) 38 924 points
(0.28%) 18 051 points
(1.04%) $78.92
(0.75%) $2.16
(0.86%) $2 328.40
(2.78%) $27.43
(1.24%) $977.30
(-0.04%) $0.928
(-0.27%) $10.84
(-0.25%) $0.795
(0.02%) $91.47
3 days till quarter result
(bmo 2024-05-09)
Expected move: +/- 11.40%
@ $29.86
Utstedt: 11 mar 2024 @ 16:11
Avkastning: -20.96%
Forrige signal: mar 11 - 14:31
Forrige signal:
Avkastning: -1.35 %
Live Chart Being Loaded With Signals
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency...
Stats | |
---|---|
Dagens volum | 1.29M |
Gjennomsnittsvolum | 1.48M |
Markedsverdi | 2.28B |
EPS | $0 ( 2024-05-02 ) |
Neste inntjeningsdato | ( $-1.350 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.35 |
ATR14 | $0.0260 (0.11%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-10 | Dube Michael P | Sell | 0 | Common Stock |
2024-03-01 | Sepp-lorenzino Laura | Buy | 37 966 | Common Stock |
2024-03-01 | Sepp-lorenzino Laura | Buy | 54 794 | Stock Option (right to buy) |
2024-03-01 | Basta James | Buy | 32 394 | Common Stock |
2024-03-04 | Basta James | Sell | 2 297 | Common Stock |
INSIDER POWER |
---|
85.54 |
Last 100 transactions |
Buy: 1 561 723 | Sell: 123 854 |
Volum Korrelasjon
Intellia Therapeutics Inc Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
PYCR | 0.85 |
NVIV | 0.838 |
RKDA | 0.833 |
BIOC | 0.826 |
LAZY | 0.822 |
CDZI | 0.82 |
HUGE | 0.818 |
SBUX | 0.818 |
TNXP | 0.806 |
RGP | 0.804 |
10 Mest negative korrelasjoner | |
---|---|
UIHC | -0.813 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Intellia Therapeutics Inc Korrelasjon - Valuta/Råvare
Intellia Therapeutics Inc Økonomi
Annual | 2023 |
Omsetning: | $36.28M |
Bruttogevinst: | $27.30M (75.26 %) |
EPS: | $-5.42 |
FY | 2023 |
Omsetning: | $36.28M |
Bruttogevinst: | $27.30M (75.26 %) |
EPS: | $-5.42 |
FY | 2022 |
Omsetning: | $52.12M |
Bruttogevinst: | $44.55M (85.47 %) |
EPS: | $-6.37 |
FY | 2021 |
Omsetning: | $33.05M |
Bruttogevinst: | $33.05M (100.00 %) |
EPS: | $-3.78 |
Financial Reports:
No articles found.
Intellia Therapeutics Inc
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.